激素受体阳性乳腺癌靶向治疗的研究进展
Research Advances in Targeted Therapies for Luminal Breast Cancer
摘要: 乳腺癌是女性发病率最高的癌症，激素受体阳性乳腺癌因其拥有针对性的医治成为乳腺癌临床研究的关注点，分子靶向治疗已成为乳腺癌治疗的新风向，靶向药物联合内分泌治疗已经改变了激素受体阳性乳腺癌临床实践，本篇文章将在激素受体阳性乳腺癌的临床病理特征的基础之上，对其常见的靶点、信号通路，如：细胞周期蛋白依赖性激酶4和6 (Cyclin-dependent kinases 4 and 6, CDK4/6)、脂酰肌醇3⁃激酶(PI3K)/蛋白激酶B (AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路(Lipodylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target rapamycin (mTOR))，即PAM信号通路、组蛋白去乙酰化酶(histone deacetylase, HDAC)及其对应的靶向药物的最新研究进展做概述。
Abstract: Breast cancer is the highest incidence of cancer in women, luminal breast cancer because of its tar-geted treatment has become a hot spot in clinical research of breast cancer, molecular targeted therapy has become a new trend in breast cancer treatment, targeted drugs combined with endo-crine therapy has changed the clinical practice of lumen breast cancer, this article will be on the ba-sis of the clinicopathological characteristics of cavity-faced breast cancer, on the basis of its common targets, signaling pathways, such as cyclin-dependent kinases 4 and 6 (CDK4/6), PAM signaling pathway, recent research advances in histone deacetylase (HDAC) and its corresponding targeted drugs are outlined.
文章引用：马秀英, 迪力努尔·艾麦提, 王薇. 激素受体阳性乳腺癌靶向治疗的研究进展[J]. 临床医学进展, 2023, 13(10): 16071-16076. https://doi.org/10.12677/ACM.2023.13102245

参考文献

[1] 孙雪竹. 三阴型乳腺癌的最新治疗研究进展(综述) [J]. 安徽卫生职业技术学院学报, 2020, 19(1): 123-125.
[2] Goldner, M., Pandolfi, N., Maciel, D., et al. (2021) Combined Endocrine and Targeted Therapy in Lu-minal Breast Cancer. Expert Review of Anticancer Therapy, 21, 1237-1251. [Google Scholar] [CrossRef] [PubMed]
[3] 秦娟, 宋冬. 乳腺癌不同时期治疗方式的研究进展[J]. 医学理论与实践, 2022, 35(12): 2023-2025.
[4] 水若鸿, 杨文涛, 龚西騟. 激素受体阳性乳腺癌的临床病理特征和研究进展[J]. 临床与实验病理学杂志, 2013, 29(3): 235-239.
[5] Ades, F., Zardavas, D., Bozovic-Spasojevic, I., et al. (2014) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Jour-nal of Clinical Oncology, 32, 2794-2803. [Google Scholar] [CrossRef] 
[6] Prat, A., Pineda, E., Adamo, B., et al. (2015) Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer. Breast, 24, S26-S35. [Google Scholar] [CrossRef] [PubMed]
[7] Hashmi, A.A., Aijaz, S., Khan, S.M., et al. (2018) Prognostic Parameters of Luminal A and Luminal B Intrinsic Breast Cancer Subtypes of Pakistani Patients. World Journal of Surgi-cal Oncology, 16, 1. [Google Scholar] [CrossRef] [PubMed]
[8] 李香, 沈莉菁. 细胞周期依赖性蛋白激酶及细胞周期蛋白D在血液系统恶性肿瘤中的作用[J]. 国际输血及血液学杂志, 2018(3): 256-260.
[9] Ma, C.X., Gao, F., Luo, J., et al. (2017) NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 23, 4055-4065. [Google Scholar] [CrossRef] 
[10] Scott, S.C., Lee, S.S. and Abraham, J. (2020) Mechanisms of Therapeutic CDK4/6 Inhibition in Breast Cancer. Seminars in Oncology, 44, 385-394. [Google Scholar] [CrossRef] [PubMed]
[11] 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版) [J]. 中华肿瘤杂志, 2020(10): 781-797.
[12] 赵晶, 吴楠, 张世超, 等. 乳腺癌靶向治疗新进展[J]. 中华肿瘤杂志, 2020, 42(5): 353-361.
[13] Loibl, S. and Furlanetto, J. (2022) Integrating CDK4/6 Inhibitors in the Treatment of Patients with Early Breast Cancer. Breast, 62, S70-S79. [Google Scholar] [CrossRef] [PubMed]
[14] Gil-Gil, M., Alba, E., Gavila, J., et al. (2021) The Role of CDK4/6 Inhibitors in Early Breast Cancer. Breast, 58, 160-169. [Google Scholar] [CrossRef] [PubMed]
[15] 江泽飞, 许凤锐. 乳腺癌精准治疗: 20年探索历程[J]. 中国实用外科杂志, 2020, 40(1): 83-88.
[16] 王文艺. 乳腺癌脑转移的特点及治疗研究进展[J]. 临床肿瘤学杂志, 2022, 27(3): 265-272.
[17] 张文歆, 陈海飞, 戚慧洁, 等. 细胞周期蛋白依赖性激酶4/6抑制剂的研究进展[J]. 上海医药, 2020, 41(15): 13-17.
[18] Harbeck, N., Rastogi, P., Martin, M., et al. (2021) Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis from the monarchE Study. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 32, 1571-1581.
[19] 钱瑶, Liu Feng. 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649.
[20] 罗锦琳, 欧阳慧婷, 邹联洪, 等. 乳腺癌内分泌耐药机制的研究进展[J]. 实用预防医学, 2022, 29(4): 510-513.
[21] Nunnery, S.E. and Mayer, I.A. (2020) Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 80, 1685-1697. [Google Scholar] [CrossRef] [PubMed]
[22] 中国抗癌协会肿瘤药物临床研究专业委员会, 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会肿瘤病理专业委员会, 等. PI3K/AKT/mTOR信号通路抑制剂治疗乳腺癌临床应用专家共识[J]. 中华肿瘤杂志, 2022(7): 673-692.
[23] 李佩瑜, 田富国. PI3K-AKT-mTOR信号通路抑制剂靶向治疗三阴性乳腺癌的研究进展[J]. 肿瘤研究与临床, 2020, 32(8): 525-528.
[24] 宋高锋. 依维莫司治疗晚期乳腺癌激素受体阳性患者中位生存期的影响因素分析[J]. 中国药物与临床, 2022, 22(1): 49-51.
[25] 许光亚, 王婷, 李斌, 等. 乳腺癌的靶向治疗研究进展[J]. 中国药物经济学, 2021, 16(9): 125-128.
[26] 李媛媛, 张斌, 张月, 等. SB939诱导乳腺癌细胞周期阻滞和凋亡的作用及机制[J]. 中华实验外科杂志, 2012(5): 790-792.
[27] 李志英, 李西川. 表观遗传调控类新药西达苯胺的抗肿瘤作用及其机制研究进展[J]. 中国肿瘤生物治疗杂志, 2021, 28(6): 611-615.

为你推荐